Literature DB >> 15907546

Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.

N V Todd1, J Morrow, K Doh-ura, S Dealler, S O'Hare, P Farling, M Duddy, N G Rainov.   

Abstract

Variant Creutzfeldt-Jakob disease (CJD) is a transmissible spongiform encephalopathy believed to be caused by the bovine spongiform encephalopathy agent, an abnormal isoform of the prion protein (PrP(sc)). At present there is no specific or effective treatment available for any form of CJD. Pentosan polysulphate (PPS), a large polyglycoside molecule with weak heparin-like activity, has been shown to prolong the incubation period of the intracerebral infection when administered to the cerebral ventricles in a rodent scrapie model. PPS also prevents the production of further PrP(sc) in cell culture models. These properties of PPS prompted its cerebroventricular administration in a young man with vCJD. Long-term continuous infusion of PPS at a dose of 11 microg/kg/day for 18 months did not cause drug-related side effects. Follow-up CT scans demonstrated progressive brain atrophy during PPS administration. Further basic and clinical research is needed in order to address the issue of efficacy of PPS in vCJD and in other prion diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907546     DOI: 10.1016/j.jinf.2004.07.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  18 in total

1.  Enhanced antiscrapie effect using combination drug treatment.

Authors:  David A Kocisko; Byron Caughey; John D Morrey; Richard E Race
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

2.  Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease.

Authors:  Gregory J Raymond; Emily A Olsen; Kil Sun Lee; Lynne D Raymond; P Kruger Bryant; Gerald S Baron; Winslow S Caughey; David A Kocisko; Linda E McHolland; Cynthia Favara; Jan P M Langeveld; Fred G van Zijderveld; Richard T Mayer; Michael W Miller; Elizabeth S Williams; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  A porphyrin increases survival time of mice after intracerebral prion infection.

Authors:  David A Kocisko; Winslow S Caughey; Richard E Race; Grant Roper; Byron Caughey; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

5.  Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.

Authors:  Valentina Villa; Michele Tonelli; Stefano Thellung; Alessandro Corsaro; Bruno Tasso; Federica Novelli; Caterina Canu; Albiana Pino; Katia Chiovitti; Domenico Paludi; Claudio Russo; Anna Sparatore; Antonio Aceto; Vito Boido; Fabio Sparatore; Tullio Florio
Journal:  Neurotox Res       Date:  2010-04-20       Impact factor: 3.911

6.  Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.

Authors:  A Parry; I Baker; R Stacey; S Wimalaratna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-21       Impact factor: 10.154

7.  Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231.

Authors:  Alessandro Corsaro; Stefano Thellung; Katia Chiovitti; Valentina Villa; Alessandro Simi; Federica Raggi; Domenico Paludi; Claudio Russo; Antonio Aceto; Tullio Florio
Journal:  Neurotox Res       Date:  2009-02-26       Impact factor: 3.911

8.  Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.

Authors:  David A Kocisko; Andrew Vaillant; Kil Sun Lee; Kevin M Arnold; Nadine Bertholet; Richard E Race; Emily A Olsen; Jean-Marc Juteau; Byron Caughey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  A synthetic heparinoid blocks Tau aggregate cell uptake and amplification.

Authors:  Barbara E Stopschinski; Talitha L Thomas; Sourena Nadji; Eric Darvish; Linfeng Fan; Brandon B Holmes; Anuja R Modi; Jordan G Finnell; Omar M Kashmer; Sandi Estill-Terpack; Hilda Mirbaha; Hung S Luu; Marc I Diamond
Journal:  J Biol Chem       Date:  2020-01-23       Impact factor: 5.157

10.  Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.

Authors:  Maxime Lefebvre-Roque; Elisabeth Kremmer; Sabine Gilch; Wen-Quan Zou; Cécile Féraudet; Chantal Mourton Gilles; Nicole Salès; Jacques Grassi; Pierluigi Gambetti; Thierry Baron; Hermann Schätzl; Corinne Ida Lasmézas
Journal:  Prion       Date:  2007-07-15       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.